KoaburasideCAS# 41653-73-0 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 41653-73-0 | SDF | Download SDF |
| PubChem ID | 5318820 | Appearance | Powder |
| Formula | C14H20O9 | M.Wt | 332.3 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2S,3R,4S,5S,6R)-2-(4-hydroxy-3,5-dimethoxyphenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| SMILES | COC1=CC(=CC(=C1O)OC)OC2C(C(C(C(O2)CO)O)O)O | ||
| Standard InChIKey | SWHCKWOYUSDWOF-RGCYKPLRSA-N | ||
| Standard InChI | InChI=1S/C14H20O9/c1-20-7-3-6(4-8(21-2)10(7)16)22-14-13(19)12(18)11(17)9(5-15)23-14/h3-4,9,11-19H,5H2,1-2H3/t9-,11-,12+,13-,14-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Koaburaside can suppress histamine release from mast cells, it may have anti-allergic inflammatory activity. 2. Koaburaside exhibits antioxidant activity with an IC50 value of 9.0μM, it shows weak inhibitory activity against influenza A neuraminidase. |
| Targets | IL Receptor | TNF-α | Influenza virus |
Koaburaside Dilution Calculator
Koaburaside Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0093 mL | 15.0466 mL | 30.0933 mL | 60.1866 mL | 75.2332 mL |
| 5 mM | 0.6019 mL | 3.0093 mL | 6.0187 mL | 12.0373 mL | 15.0466 mL |
| 10 mM | 0.3009 mL | 1.5047 mL | 3.0093 mL | 6.0187 mL | 7.5233 mL |
| 50 mM | 0.0602 mL | 0.3009 mL | 0.6019 mL | 1.2037 mL | 1.5047 mL |
| 100 mM | 0.0301 mL | 0.1505 mL | 0.3009 mL | 0.6019 mL | 0.7523 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Lacinilene C
Catalog No.:BCN5474
CAS No.:41653-72-9
- Ciclopirox ethanolamine
Catalog No.:BCC4372
CAS No.:41621-49-2
- Ylangenol
Catalog No.:BCN6705
CAS No.:41610-69-9
- (-)-Pinoresinol 4-O-glucoside
Catalog No.:BCN7251
CAS No.:41607-20-9
- 4,R-ajmalicine N-oxide
Catalog No.:BCN5473
CAS No.:41590-29-8
- Carboplatin
Catalog No.:BCC1170
CAS No.:41575-94-4
- Poricoic acid G
Catalog No.:BCN8267
CAS No.:415724-84-4
- RI-1
Catalog No.:BCC1896
CAS No.:415713-60-9
- SN-6
Catalog No.:BCC7273
CAS No.:415697-08-4
- N6-Cyclopentyladenosine
Catalog No.:BCC7160
CAS No.:41552-82-3
- 1-(3,4-dimethoxyphenyl)-2-(4-allly-2,6-dimethoxyphenoxy)propan-1-ol
Catalog No.:BCN1445
CAS No.:41535-95-9
- 2,6,16-Kauranetriol
Catalog No.:BCN5472
CAS No.:41530-90-9
- 7-O-Methyl morroniside
Catalog No.:BCN3882
CAS No.:41679-97-4
- Catharanthine hemitartrate
Catalog No.:BCN8463
CAS No.:4168-17-6
- 2H-1-Benzopyran-7-yloxy
Catalog No.:BCN3580
CAS No.:41680-08-4
- 4',7-Dihydroxyflavanone
Catalog No.:BCC8333
CAS No.:41680-09-5
- 8-Methyleugenitol
Catalog No.:BCN6459
CAS No.:41682-21-7
- Arctigenin 4'-O-beta-gentiobioside
Catalog No.:BCN2847
CAS No.:41682-24-0
- 8-Acetoxypentadeca-1,9Z-diene-4,6-diyn-3-ol
Catalog No.:BCN1444
CAS No.:41682-30-8
- Epiaschantin
Catalog No.:BCN7206
CAS No.:41689-50-3
- Epimagnolin A
Catalog No.:BCN7831
CAS No.:41689-51-4
- Indicine N-oxide
Catalog No.:BCN1996
CAS No.:41708-76-3
- Croalbidine
Catalog No.:BCN2068
CAS No.:41714-30-1
- Bavachromene
Catalog No.:BCN3191
CAS No.:41743-38-8
Phenolic glycosides from Lindera obtusiloba and their anti-allergic inflammatory activities.[Pubmed:23513723]
Nat Prod Commun. 2013 Feb;8(2):181-2.
Eight phenolic glycosides, tachioside (1), isotachioside (2), Koaburaside (3), 2,6-dimethoxy-4-hydroxyphenyl-1-O-beta-D-glucopyranoside (4), 4,6-dihydroxy-2-methoxyphenyl-1-O-beta-D-glucopyranoside (5), a mixture of erigeside C (6a) and salidroside (6b), and 6-hydroxyphenyl)-1-O-beta-D-glucopyranoside (7) were isolated from the stems of Lindera obtusiloba Blume. The structures of the isolates were determined by 1H-, 13C-NMR, COSY, HMQC, and HMBC spectroscopy. To evaluate their anti-allergic inflammatory activities, the inhibitory effects of isolates (1-7) on histamine release and on the gene expressions of tumor necrosis factor (TNF)-a and interleukin (IL)-6 were examined using human mast cells; previous studies have reported that TNF-alpha and IL-6 release from mast cells is positively related to the severity of allergic symptoms. Of the tested compounds, Koaburaside (3), 2,6-dimethoxy-4-hydroxyphenyl-1-O-beta-D-glucopyranoside (4), and (6-hydroxyphenyl)-1-O-beta-D-glucopyranoside (7) suppressed histamine release from mast cells as compared with gallic acid (positive control). In particular, 6-hydroxyphenyl)-1-O-beta-D-glucopyranoside (7) attenuated the gene expressions of the proinflammatory cytokines TNF-alpha and IL-6 in human mast cells. Our results support the notion that phenolic glycosides isolated from L. obtusiloba inhibit mast-cell-derived allergic inflammation, histamine, and proinflammatory cytokines.
